Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Neurobiol Dis. 2010 Jan 18;38(2):210–218. doi: 10.1016/j.nbd.2010.01.007

Fig. 4.

Fig. 4

Immunoreactivity of TRIM9 in the brain of controls (A, D) and patients with dementia with Lewy bodies (DLB) (B, C) and Parkinson’s disease (E, F). TRIM9 immunoreactivity in the neuronal cytoplasm is severely decreased in DLB temporal cortex (B) compared with controls (A). Decrease of TRIM9 immunoreactivity in the neuronal cytoplasm in PD substantia nigra (E) compared with controls (D). TRIM9 immunoreactivity in cortical Lewy bodies in the temporal lobe (C, arrowheads) and brainstem-type Lewy bodies in the substantia nigra (F). Bars = 20 μm.